{"id":"cfc99c8491bb","type":"article","url":"https://hartvaat.nl/2018/02/01/herstel-zonder-hartfalen-na-acs-en-revascularisatie/","title":"Herstel zonder hartfalen na ACS en revascularisatie","title_en":"Recovery free of heart failure after acute coronary syndrome and coronary revascularization.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-coronair-syndroom","acuut-hartfalen","myocardinfarct"],"journal":"ESC heart failure","doi":"10.1002/ehf2.12197","source_url":"https://doi.org/10.1002/ehf2.12197","authors":["Alec Falkenham","Manoj K Saraswat","Chloe Wong","Kareem Gawdat","Tanya Myers","Jahanara Begum","Karen J Buth","Ian Haidl","Jean Marshall","Jean-Francois Légaré"],"significance":5,"published":"2018-02-01","source_date":"2018-02-01","image":"","kennis":[],"congress":"","summary_en":"This study characterized recovery from heart failure after acute coronary syndrome and coronary revascularization, identifying factors associated with freedom from HF events after successful treatment.","created":"2026-07-03T10:27:07Z","updated":"2026-07-03T18:38:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie naar herstel van hartfunctie en vrijheid van hartfalen na ACS en coronaire revascularisatie. Prognose na succesvolle revascularisatie bij initieel verminderde LV-functie.","abstract_original":"AIMS: Previous studies have examined risk factors for the development of heart failure (HF) subsequent to acute coronary syndrome (ACS). Our study seeks to clarify the clinical variables that best characterize patients who remain free from HF after coronary artery bypass grafting (CABG) surgery for ACS to determine novel biological factors favouring freedom from HF in prospective translational studies. METHODS AND RESULTS: Nova Scotia residents (1995-2012) undergoing CABG within 3 weeks of ACS were included. The primary outcome was freedom from readmission to hospital due to HF. Descriptive statistics were generated, and a Cox proportional hazards model assessed outcome with adjustment for clinical characteristics. Of 11 936 Nova Scotians who underwent isolated CABG, 3264 (27%) had a recent ACS and were included. Deaths occurred in 210 (6%) of subjects prior to discharge. A total of 3054 patients were included in the long-term analysis. During follow-up, HF necessitating readmission occurred in 688 (21%) subjects with a hazard ratio of 12% at 2 years. The adjusted Cox model demonstrated significantly better freedom from HF for younger, male subjects without metabolic syndrome and no history of chronic obstructive pulmonary disease, renal insufficiency, atrial fibrillation, or HF. CONCLUSIONS: Our findings have outlined important clinical variables that predict freedom from HF. Furthermore, we have shown that 12% of patients undergoing CABG after ACS develop HF (2 years). Our findings support our next phase in which we plan to prospectively collect blood and tissue specimens from ACS patients undergoing CABG in order to determine novel biological mechanism(s) that favour resolution of post-ACS inflammation."}